AbbVie (ABBV) Change in Taxes (2019 - 2026)
AbbVie (ABBV) posted quarterly Change in Taxes of -$81.0 million for Q1 2026, down 121.43% year-over-year from $378.0 million in Q1 2025, and down 112.54% quarter-over-quarter from $646.0 million in Q4 2025.
AbbVie (ABBV) Change in Taxes (2019 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Change in Taxes for 8 consecutive years, with -$81.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Taxes fell 121.43% year-over-year to -$81.0 million; the TTM figure through Mar 2026 stood at -$1.2 billion (up 61.94% YoY), while the FY2025 annual figure was -$762.0 million, up 76.25% from the prior year.
- Change in Taxes slipped to -$81.0 million in Q1 2026 per ABBV's latest filing, from $646.0 million in the prior quarter.
- Across five years, Change in Taxes topped out at $646.0 million in Q4 2025 and bottomed at -$1.8 billion in Q2 2024.
- Historically, Change in Taxes has averaged -$235.1 million across 5 years, with a median of $51.0 million in 2024.
- Annual changes were most pronounced in 2022 — Change in Taxes soared 545.45% — and 2025, when it plunged 905.88%.
- AbbVie's Change in Taxes stood at $358.0 million in 2022, then climbed by 14.8% to $411.0 million in 2023, then sank by 538.69% to -$1.8 billion in 2024, then jumped by 135.83% to $646.0 million in 2025, then tumbled by 112.54% to -$81.0 million in 2026.
- Business Quant data shows ABBV's Change in Taxes at -$81.0 million in Q1 2026, $646.0 million in Q4 2025, and -$411.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -2.22 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -131.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 171.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.22 Bn |
| Jun 30, 2026 | -2.22 Bn |
| Mar 31, 2026 | -81.00 Mn |
| Mar 31, 2026 | -81.00 Mn |
| Dec 31, 2025 | 646.00 Mn |
| Dec 31, 2025 | 646.00 Mn |
| Sep 30, 2025 | -411.00 Mn |
| Sep 30, 2025 | -411.00 Mn |
| Jun 30, 2025 | -1.38 Bn |
| Jun 30, 2025 | -1.38 Bn |
| Mar 31, 2025 | 378.00 Mn |
| Mar 31, 2025 | 378.00 Mn |
| Dec 31, 2024 | -1.80 Bn |
| Dec 31, 2024 | -1.80 Bn |
| Sep 30, 2024 | 51.00 Mn |
| Sep 30, 2024 | 51.00 Mn |
| Jun 30, 2024 | -1.83 Bn |
| Jun 30, 2024 | -1.83 Bn |
| Mar 31, 2024 | 378.00 Mn |
| Mar 31, 2024 | 378.00 Mn |